Ester Simeone

8.4k total citations · 1 hit paper
114 papers, 4.4k citations indexed

About

Ester Simeone is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ester Simeone has authored 114 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Oncology, 56 papers in Molecular Biology and 46 papers in Immunology. Recurrent topics in Ester Simeone's work include Melanoma and MAPK Pathways (45 papers), Cancer Immunotherapy and Biomarkers (43 papers) and CAR-T cell therapy research (34 papers). Ester Simeone is often cited by papers focused on Melanoma and MAPK Pathways (45 papers), Cancer Immunotherapy and Biomarkers (43 papers) and CAR-T cell therapy research (34 papers). Ester Simeone collaborates with scholars based in Italy, United States and Malaysia. Ester Simeone's co-authors include Paolo A. Ascierto, Antonio Maria Grimaldi, Diana Giannarelli, Corrado Caracò, Lucia Festino, Vito Vanella, Nicola Mozzillo, Paola Queirolo, Giuseppe Palmieri and Michele Maio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ester Simeone

114 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

2018 351 citations Mariaelena Capone, Diana Giannarelli et al. Journal for ImmunoTherapy of Cancer profile →

Peers

Countries citing papers authored by Ester Simeone

Since Specialization

Citations

This map shows the geographic impact of Ester Simeone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ester Simeone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ester Simeone more than expected).

Fields of papers citing papers by Ester Simeone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ester Simeone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ester Simeone. The network helps show where Ester Simeone may publish in the future.

Co-authorship network of co-authors of Ester Simeone

This figure shows the co-authorship network connecting the top 25 collaborators of Ester Simeone. A scholar is included among the top collaborators of Ester Simeone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ester Simeone. Ester Simeone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunotherapy Assessment: A New Paradigm for Radiologists 2023 ·Diagnostics ·Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Igino Simonetti, Carmine Picone, Ester Simeone, Lucia Festino, Vito Vanella, Maria Grazia Vitale, Agnese Montanino, Alessandro Morabito, Francesco Izzo, Paolo A. Ascierto, Antonella Petrillo	4
2	Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition 2023 ·European Journal of Cancer ·Robert Ferguson, (unknown), (unknown), Danny Simpson, (unknown), (unknown), (unknown), Gabriele Madonna, Mariaelena Capone, Ester Simeone, Anna C. Pavlick, Jason J. Luke, Thomas F. Gajewski, Iman Osman, Paolo A. Ascierto, Jeffrey S. Weber, Tomas Kirchhoff	6
3	CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy 2023 ·Journal of Translational Medicine ·Domenico Mallardo, (unknown), Andrew White, Margaret Ottaviano, Francesca Sparano, Michael Bailey, (unknown), SuFey Ong, Piera Maiolino, Corrado Caracò, S. Church, Ernesta Cavalcanti, Sarah Warren, Alfredo Budillon, Alessandra Cesano, Ester Simeone, Paolo Chiodini, Paolo A. Ascierto	19
4	Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients 2023 ·Journal of Translational Medicine ·Domenico Galati, Serena Zanotta, Mariaelena Capone, Gabriele Madonna, Domenico Mallardo, (unknown), Ester Simeone, Lucia Festino, Francesca Sparano, Rosa Azzaro, Rosaria De Filippi, Antonio Pinto, Chrystal M. Paulos, Paolo A. Ascierto	8
5	Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas 2022 ·Biomedicines ·Margaret Ottaviano, Emilio Francesco Giunta, Laura Marandino, (unknown), Laura Attademo, Davide Bosso, Cinzia Cardalesi, Antonietta Fabbrocini, Mario Rosanova, Antonia Silvestri, Liliana Montella, Pasquale Tammaro, Ester Marra, Claudia Trojaniello, Maria Grazia Vitale, Ester Simeone, Teresa Troiani, Bruno Daniele, Paolo A. Ascierto	21
6	832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A202:01 patients (pts) with metastatic uveal melanoma (mUM) 2022 ·Annals of Oncology* ·Florentia Dimitriou, J.C. Hassel, Marlana Orloff, (unknown), Ellen Kapiteijn, Inderjit Mehmi, (unknown), (unknown), (unknown), Camille L. Gérard, Ester Simeone, (unknown), Phil F. Cheng, Georgina V. Long, Richard D. Carvajal, R. Dummer	3
7	Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience 2021 ·Cancers ·Valentina Borzillo, Rossella Di Franco, Diana Giannarelli, (unknown), (unknown), Emma D’Ippolito, (unknown), (unknown), Sara Falivene, Antonio Maria Grimaldi, Ester Simeone, Lucia Festino, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Gabriele Madonna, Paolo A. Ascierto, Paolo Muto	8
8	Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy 2021 ·Cancers ·Gabriele Madonna, Giuseppe Masucci, Mariaelena Capone, Domenico Mallardo, Antonio Maria Grimaldi, Ester Simeone, Vito Vanella, Lucia Festino, Marco Palla, (unknown), (unknown), (unknown), Lisa Villabona, (unknown), Hanna Eriksson, (unknown), Rolf Lewensohn, Paolo A. Ascierto	7
9	Nivolumab for the treatment of small cell lung cancer 2019 ·Expert Review of Respiratory Medicine ·Ester Simeone, Antonio Maria Grimaldi, Lucia Festino, Claudia Trojaniello, Maria Grazia Vitale, Vito Vanella, Marcello Curvietto, Paolo A. Ascierto	6
10	Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab breakdown → 2018 ·Journal for ImmunoTherapy of Cancer ·Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Gabriele Madonna, Lucia Festino, Antonio Maria Grimaldi, Vito Vanella, Ester Simeone, Miriam Paone, Giuseppe Palmieri, Ernesta Cavalcanti, Corrado Caracò, Paolo A. Ascierto	351
11	Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma 2017 ·OncoImmunology ·Ester Simeone, Antonio Maria Grimaldi, Lucia Festino, Diana Giannarelli, Vito Vanella, Marco Palla, Marcello Curvietto, Assunta Esposito, Giuseppe Palmieri, Nicola Mozzillo, Paolo A. Ascierto	30
12	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab 2017 ·OncoImmunology ·Gabriele Madonna, Carmen Ballesteros‐Merino, Zipei Feng, Carlo Bifulco, Mariaelena Capone, Diana Giannarelli, Domenico Mallardo, Ester Simeone, Antonio Maria Grimaldi, Corrado Caracò, Gerardo Botti, Bernard A. Fox, Paolo A. Ascierto	46
13	PD-L1 inhibitors in the pipeline: Promise and progress 2017 ·OncoImmunology ·Vito Vanella, Lucia Festino, Martina Strudel, Ester Simeone, Antonio Maria Grimaldi, Paolo A. Ascierto	36
14	Efficacy and safety of combined sequential treatment with radiofrequency ablation and sorafenib in patients with hepatocellular carcinoma in intermediate stage ineligible for tace: a prospective randomized open study 2015 ·Annals of Oncology ·G. de Stefano, U. Scognamiglio, V. Iodice, Nunzia Farella, Ester Simeone, Vincenzo Montesarchio	1
15	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy 2015 ·OncoImmunology ·Nicola Mozzillo, Ester Simeone, (unknown), Marcello Curvietto, Diana Giannarelli, Giusy Gentilcore, Rosa Camerlingo, Mariaelena Capone, Gabriele Madonna, Lucia Festino, Corrado Caracò, Gianluca Di Monta, Ugo Marone, Massimiliano Di Marzo, Antonio Maria Grimaldi, Stefano Mori, Gennaro Ciliberto, Paolo A. Ascierto	55
16	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma 2013 ·Journal of Clinical Oncology ·Paolo A. Ascierto, David R. Minor, Antoni Ribas, Célèste Lebbé, Anne O’Hagan, Niki Arya, Mary Guckert, Dirk Schadendorf, Richard Kefford, Jean‐Jacques Grob, Omid Hamid, Ravi K. Amaravadi, Ester Simeone, Tabea Wilhelm, Kevin B. Kim, Georgina V. Long, Anne-Marie Martin, Jolly Mazumdar, Vicki Goodman, Uwe Trefzer	338
17	Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma 2013 ·Journal of Translational Medicine ·Antonio Daponte, Simona Signoriello, Luigi Maiorino, B. Massidda, Ester Simeone, Antonio Maria Grimaldi, Corrado Caracò, Giuseppe Palmieri, Antonio Cossu, Gerardo Botti, Antonella Petrillo, Secondo Lastoria, Ernesta Cavalcanti, (unknown), Nicola Mozzillo, Ciro Gallo, Giuseppe Comella, Paolo A. Ascierto	23
18	Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report 2012 ·Journal of Medical Case Reports ·Ester Simeone, (unknown), Fabio Sandomenico, Franco Fulciniti, Secondo Lastoria, (unknown), Stefania Staibano, Vincenzo Montesarchio, Giuseppe Palmieri, Nicola Mozzillo, Paolo A. Ascierto	19
19	Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1 2012 ·Journal of Immunotoxicology ·Ester Simeone, Paolo A. Ascierto	69
20	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy 2006 ·European Journal of Cancer ·Milena Casula, Maria Colombino, María Paola Satta, Antonio Cossu, Amelia Lissia, Mario Budroni, Ester Simeone, Rosa Calemma, (unknown), Corrado Caracò, Nicola Mozzillo, Antonio Daponte, Giuseppe Comella, (unknown), Michele Guida, Giuseppe Castello, Paolo A. Ascierto, Giuseppe Palmieri	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact